Background and Aims: Baracos group developed a useful method with clinical CT images to investigate muscle wasting. We applied this technique to colorectal cancer patients, in a subset of whom we investigated muscle metabolism. Methods: We analysed CT images (psoas major, L-3; gluteus maximus, coccyx) for patients with colorectal cancers (n ¼ 65,73 AE 11y) and patients who proved normal on investigation(n ¼ 56,71 AE 11y). In a subset (n ¼ 18,74 AE 10y) of the cancer patients, we also characterized muscle metabolism by stable-tracer and molecular methods. Results: In the healthy patients, psoas thickness was 30(28,31) mm (median (95%CI)) and 31(26,30) mm in cancer patients. Normal gluteus thickness was 30(31,36) mm; 29(32,38) mm in patients; normal psoas cross sectional area (CSA) was 2873(2708,3299) mm2 and in patients was 3049(2561,4155) mm2. In metabolism subset, psoas thickness was 30(28, 35) mm, gluteus thickness was 36(32, 38) mm; psoas CSA was 2973(2442, 3074) mm2. Thus in patients with early colorectal cancer significant wasting could not be detected by comparison with age-matched controls. However, the metabolic subset, despite only minor losses of leg muscle (2-15 g/day), showed "anabolic resistance" of MPS (fed state: 0.030 AE 0.003 vs. 0.071 AE 0.003 %/h) with no evidence of elevated MPB. Conclusion: Establishment of muscle metabolic dysfunction precedes major sarcopenia in colorectal cancer. 
DICHLOROACETATE INDUCES APOPTOSIS AND CELL-CYCLE ARREST IN COLORECTAL CANCER CELLS BUT NOT IN NON-CANCEROUS CELLS
Neuroblastoma is the commonest extra-cranial solid-tumour of peripheral sympathetic NS in children and leading cause of cancer-related deaths in childhood(1-4Y). Tumour-cells take up, store and secrete catecholamine metabolites and express the norepinephrine transporter, making metaiodobenzylguanidine (MIBG)-an analogue of norepinephrine-an ideal tumour-specific agent for imaging and therapy when labelled with 131I or 123I. This randomised controlled trial presents our experience in using 131I-MIBG upfront therapy in diagnosing and treating Neuroblastoma. Thirty-four patients had their treatment up-fronted by 3-4 cycles of 131 I-MIBG every 21-28 days guided by haematological recovery (Group A) followed by first-line chemotherapy. Surgical intervention varied according to response aiming at complete tumour-clearance. 
